Clinically, this newly discovered antagonistic relationship between PRL/PRLR and YAP-CCN2 pathways was further explored and extended to large gene expression datasets of normal and breast cancer cases as well as 33 other cancer types allowing the discovery of a PRLR/Hippo pathway gene co-expression network of favorable prognosis in breast cancer. The gene discussed is PRL; the disease is breast carcinoma.